Part:BBa_K3522001
This composite part is a platform to screen a small molecule FXR antagonist.
Sequence and Features
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal XhoI site found at 749
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
BBa_K3522001 contains T7 promoter, His tag, FXR ligand-binding domain(FXR-LBD), and T7 terminator. Farnesoid X receptor (FXR) belongs to a member of the nuclear receptor Superfamily and has been reported to be associated with glucose metabolism. For example, in FXR−/− mice, the level of hepatic gluconeogenic gene expression was decreased after fasting, while blood glucose level and the hepatic glucose production in response to pyruvate challenge were declined.
Contribution
Usage and Biology Farnesoid X receptor (FXR) is a member of metabolism related nuclear receptor family. FXR agonists have been reported to improve blood glucose levels by increasing insulin sensitivity. However, there are some side effects such as lowering the level of high density lipoprotein (HDL) and aggravating obesity after long-term administration of FXR. The antagonistic FXR can reduce body weight and blood glucose, especially can better control postprandial blood glucose. Therefore, the research of FXR antagonists is also one of the hot spots of anti-metabolic diseases. At present, the effect and mechanism of FXR on glucose metabolism are not clear. Therefore, it is important to screen a small molecule FXR antagonist as a probe to explore the mechanism of FXR regulating glucose metabolism.
Engineering Success
The BBa_K3522001 was designed to conduct FXR antagonist screening screening.
Following were our experiments and results:
Recombinant FXR ligand binding domain production and purification DNA sequence of the FXR ligand binding domain (FXR-LBD) was cloned to the pET-15b vector and transferred to the BL21 (DE3) competent cells. The transformed cells were inoculated into fresh LB medium for recombinant FXR-LBD production. When the optical density of the culture reached 0.6, IPTG at final concentration of 0.2 mM was added. The expression cells were harvested by centrifugation and broken by sonication on ice. Proteins in supernatant was purified by Ni-NTA column using an AKTA FPLC instrument according to the protocol. The protein production and purification were analyzed by SDS-PAGE. As shown in Figure 1, recombinant FXR-LBD was purified to homogeneity.
Figure 1. SDS-PAGE analysis of recombinant FXR-LBD production and purification. Land 1, 2, 9: protein molecular weight standards. Lane 3: the insoluble proteins in expression cells. Lane 4: the soluble proteins in expression cells. Lane 5: the proteins in the flow through of Ni-NTA column. Lane 6 and 7: eluting fractions of FXR-LBD.
Application of recombinant FXR-LBD for FXR antagonist screening FXR antagonists screened in Lab in-house compound library by AlphaScreen technology-based assay. Alphascreen technology is used for in vitro high-throughput detection of protein interactions. In the system we constructed, we used the ability of 6×His-FXR-LBD protein and Biotin-SRC1 small peptide to bind to each other, and added Nickel chelate acceptor beads and Streptavidin donor beads. When protein and small peptide are combined with each other, the distance between the two magnetic beads is close. Under the irradiation of excitation light with wavelength of 680 nm, the photosensitizer on the donor magnetic beads converts the surrounding oxygen into monomer oxygen, and the monomer oxygen diffuses to the receptor. The bulk magnetic beads activate the fluorescent groups on the acceptor magnetic beads. Furthermore, the intensity of the interaction between the protein and the small peptide was characterized by detecting the fluorescence value at the wavelength of 520-620 nm. During the operation, we dissolve 6×His-FXR-LBD protein and SRC1 small peptide on ice, and dilute to a certain concentration with assay buffer (25 mM Hepes, pH 7.4, 100 mM NaCl and 0.1% BSA). Take a white 384 ELISA plate, add 100 nM 6×His-FXR-LBD protein, 30 nM SRC1, 0.5 μM GW4064 (FXR agonist), the selected compound, and 10 μg/mL acceptor beads to each well. Afterwards, shake the plate at 300 rpm for 10 min and incubate at room temperature for 30 min. Then add the final concentration of 10 μg/mL Donor beads 300 rpm shaker for 10 minutes, and incubate for 2 hours at room temperature in the dark. Then use PerkinElmer machine to check the fluorescence value.
Figure 2. H7 as an FXR antagonist inhibited FXR activity.The effect of compounds (20μM) on the combination of FXR-LBD and SRC-1 was detected by AlphaScreen-based protein-peptide interaction assay. A. Among the compounds, H7 was finally selected for its highly antipathogenic activity against FXR. B. H7 antagonized GW4064-induced AlphaScreen signal. All data were presented as mean ± S.E.M (*P<0.05, **P< 0.01, ***P< 0.001).
As indicated in Figure 2A and 2B, compound H7 antagonized the GW4064-induced promotion of FXR-LBD binding to its coactivator SRC-1. These results thus implied the antagonistic feature of H7 against FXR. Hence, these results proved the expected functions of our BBa_K3522001.
| None |